| Entry |
|
|---|
| Name |
Buprenorphine hydrochloride (JP18/USP);
Buprenex (TN) |
|---|
| Product |
|
|---|
| Generic |
BUPRENORPHINE (Actavis Pharma), BUPRENORPHINE (American Health Packaging), BUPRENORPHINE (AvPAK), BUPRENORPHINE (Bryant Ranch Prepack), BUPRENORPHINE (Bryant Ranch Prepack), BUPRENORPHINE (Bryant Ranch Prepack), BUPRENORPHINE (Bryant Ranch Prepack), BUPRENORPHINE (Bryant Ranch Prepack), BUPRENORPHINE (Clinical Solutions Wholesale), BUPRENORPHINE (Clinical Solutions Wholesale), BUPRENORPHINE (Clinical Solutions Wholesale), BUPRENORPHINE (RedPharm Drug), BUPRENORPHINE (Redpharm drug), BUPRENORPHINE (Rhodes Pharmaceuticals L.P.), BUPRENORPHINE (Sun Pharmaceutical Industries), BUPRENORPHINE HCL (Bryant Ranch Prepack), BUPRENORPHINE HCL (Clinical Solutions Wholesale), BUPRENORPHINE HCL (Hikma Pharmaceuticals USA), BUPRENORPHINE HCL (Major Pharmaceuticals), BUPRENORPHINE HCL (REMEDYREPACK), BUPRENORPHINE HYDROCHLORIDE (A-S Medication Solutions), BUPRENORPHINE HYDROCHLORIDE (Advagen Pharma), BUPRENORPHINE HYDROCHLORIDE (Akorn Operating Company LLC (dba Akorn)), BUPRENORPHINE HYDROCHLORIDE (ENDO USA), BUPRENORPHINE HYDROCHLORIDE (Hikma Pharmaceuticals USA), BUPRENORPHINE HYDROCHLORIDE (Hospira), BUPRENORPHINE HYDROCHLORIDE (PAI Holdings), BUPRENORPHINE HYDROCHLORIDE (REMEDYREPACK), BUPRENORPHINE HYDROCHLORIDE (Somerset Therapeutics), BUPRENORPHINE SUBLINGUAL (Direct_rx), BUPRENORPHINE SUBLINGUAL C-III (Direct_Rx), BUPRENORPHINE SUBLINGUAL C-III (Direct_Rx) |
|---|
| Formula |
C29H41NO4. HCl
|
|---|
| Exact mass |
503.2802
|
|---|
| Mol weight |
504.10
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Analgesic
DG01984 Opioid analgesics
DG01586 Opioid receptor antagonist
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 1149 |
| Product (DG00820): | D07132<JP/US> D00836<JP/US> |
| Product (mixture): | D10250<US> |
|
|---|
| Efficacy |
Analgesic, Opioid receptor agonist/antagonist |
|---|
| Comment |
Morphinan derivative, Oripavine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07224 | Opioid receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02A OPIOIDS
N02AE Oripavine derivatives
N02AE01 Buprenorphine
D00836 Buprenorphine hydrochloride (JP18/USP) <JP/US>
N07 OTHER NERVOUS SYSTEM DRUGS
N07B DRUGS USED IN ADDICTIVE DISORDERS
N07BC Drugs used in opioid dependence
N07BC01 Buprenorphine
D00836 Buprenorphine hydrochloride (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Analgesics
Opioid Analgesics, Long-acting
Buprenorphine
D00836 Buprenorphine hydrochloride (JP18/USP)
Anti-Addiction/Substance Abuse Treatment Agents
Opioid Dependence
Buprenorphine
D00836 Buprenorphine hydrochloride (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
114 Antipyretics and analgesics, anti-inflammatory agents
1149 Others
D00836 Buprenorphine hydrochloride (JP18/USP)
Drug groups [BR:br08330]
Analgesic
DG01984 Opioid analgesics
DG00820 Buprenorphine
D00836 Buprenorphine hydrochloride
DG01586 Opioid receptor antagonist
DG00820 Buprenorphine
D00836 Buprenorphine hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00820 Buprenorphine
D00836 Buprenorphine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Opioid
OPRM1
D00836 Buprenorphine hydrochloride (JP18/USP) <JP/US>
OPRK1
D00836 Buprenorphine hydrochloride (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00836 Buprenorphine hydrochloride
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00836
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00836
Drug groups [BR:br08330]
Analgesic
DG01984 Opioid analgesics
DG00820 Buprenorphine
DG01586 Opioid receptor antagonist
DG00820 Buprenorphine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00820 Buprenorphine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 35
1 X Cl 23.5865 -20.2981
2 C1z C 16.6051 -15.0621
3 C1z C 17.7919 -15.7602
4 C1y C 15.4182 -15.7602
5 C8y C 16.6051 -13.7356
6 C1x C 17.7919 -14.3639
7 C1y C 18.9787 -15.0621
8 C1x C 17.7919 -17.1565
9 C1x C 17.2334 -16.8074
10 C1z C 15.4182 -17.0867
11 O2x O 14.7899 -14.2243
12 C8y C 15.4880 -13.0375
13 C8y C 17.8617 -13.0375
14 C1x C 20.1656 -14.3639
15 N1y N 20.1656 -15.7602
16 C1x C 18.9785 -13.7356
17 C1y C 16.6051 -17.7848
18 C1x C 16.0466 -16.1093
19 C8y C 15.4880 -11.6412
20 C8x C 17.8617 -11.6412
21 C1b C 21.3524 -15.1319
22 C8x C 16.6749 -10.9431
23 O1a O 14.3012 -10.9431
24 C1y C 22.5392 -15.8300
25 C1x C 23.2374 -17.0169
26 C1x C 23.9355 -15.8300
27 O2a O 14.0220 -17.0867
28 C1a C 13.3238 -15.8998
29 C1d C 17.3032 -18.9717
30 C1a C 18.6995 -18.9717
31 C1d C 16.6051 -20.1585
32 O1a O 18.0013 -20.1585
33 C1a C 15.2088 -20.1585
34 C1a C 17.3032 -21.3453
35 C1a C 15.7673 -21.4151
BOND 40
1 2 6 1 #Up
2 3 7 1
3 3 8 1
4 3 9 1 #Down
5 4 10 1
6 4 11 1 #Down
7 5 12 1
8 5 13 2
9 6 14 1
10 7 15 1 #Up
11 7 16 1
12 8 17 1
13 9 18 1
14 12 19 2
15 13 20 1
16 15 21 1
17 19 22 1
18 19 23 1
19 10 17 1
20 10 18 1 #Down
21 11 12 1
22 13 16 1
23 15 14 1 #Up
24 20 22 2
25 2 3 1
26 21 24 1
27 2 4 1
28 2 5 1
29 24 25 1
30 24 26 1
31 26 25 1
32 10 27 1
33 27 28 1
34 17 29 1
35 29 30 1 #Up
36 29 31 1
37 29 32 1 #Down
38 31 33 1
39 31 34 1
40 31 35 1
|
|---|